Vir Biotechnology (VIR) Gains from Equity Investments (2021 - 2026)
Vir Biotechnology (VIR) reported Gains from Equity Investments of $170000.0 for Q1 2026, up 102.66% on a YoY basis from $83882.8 in Q1 2025, and down 93.48% sequentially from $2.6 million in Q4 2025.
Vir Biotechnology (VIR) Gains from Equity Investments (2021 - 2026) Analysis & Trends
Vir Biotechnology (VIR) has 6 years of Gains from Equity Investments data on file, last reported at $170000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Equity Investments rose 102.66% year-over-year to $170000.0; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (up 171.25% YoY), and the FY2025 full-year result was -$1.7 million, down 131.28% from the prior year.
- Gains from Equity Investments eased to $170000.0 in Q1 2026, from $2.6 million in the prior quarter.
- In the past five years, Gains from Equity Investments ranged from a high of $95.0 million in Q1 2022 to a low of -$8.9 million in Q4 2022.
- A 5-year average of $8.1 million and a median of $2.6 million in 2025 frame the typical range for Gains from Equity Investments.
- Peak annual rise in Gains from Equity Investments reached 888.34% in 2025, while the deepest fall reached 207.9% in 2025.
- Tracing VIR's Gains from Equity Investments over 5 years: stood at -$8.9 million in 2022, then soared by 111.18% to $993000.0 in 2023, then climbed by 18.03% to $1.2 million in 2024, then surged by 122.35% to $2.6 million in 2025, then tumbled by 93.48% to $170000.0 in 2026.
- Business Quant data shows VIR's Gains from Equity Investments at $170000.0 in Q1 2026, $2.6 million in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Vir Biotechnology | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 170,000.00 |
| Mar 31, 2026 | 170,000.00 |
| Dec 31, 2025 | 2.61 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Sep 30, 2025 | -1.34 Mn |
| Sep 30, 2025 | -1.34 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Mar 31, 2025 | -6.38 Mn |
| Mar 31, 2025 | -6.38 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | -1.13 Mn |
| Sep 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | -429,000.00 |
| Jun 30, 2024 | -429,000.00 |
| Mar 31, 2024 | 5.92 Mn |
| Mar 31, 2024 | 5.92 Mn |
| Dec 31, 2023 | 993,000.00 |
| Dec 31, 2023 | 993,000.00 |